Unia Europejska - estoński - EMA (European Medicines Agency)

shire pharmaceutical contracts limited - epoetiin delta - kidney failure, chronic; anemia - antianemilised preparaadid - dynepo on näidustatud täiskasvanud patsientidel kroonilise neerupuudulikkusega (crf) seotud sümptomaatilise aneemia raviks. seda võib kasutada dialüüsi ja dialüüsi mitte saavatel patsientidel.

Unia Europejska - estoński - EMA (European Medicines Agency)

baxalta innovations gmbh - susotstokog alfa - hemofiilia a. - antihemorraagilised ained - verejooksude episoodide ravi viii faktori antikehade poolt põhjustatud omandatud hemofiiliaga patsientidel. obizur'i on näidustatud täiskasvanutel.

Estonia - estoński - Ravimiamet

aurobindo pharma (malta) limited - ramipriil - tablett - 5mg 1000tk; 5mg 14tk; 5mg 56tk; 5mg 7tk; 5mg 100tk; 5mg 50tk; 5mg 42tk; 5mg 500tk; 5mg 90tk; 5mg 28tk; 5mg 20tk

Estonia - estoński - Ravimiamet

aurobindo pharma (malta) limited - ramipriil - tablett - 10mg 90tk; 10mg 30tk; 10mg 20tk; 10mg 500tk; 10mg 98tk; 10mg 100tk; 10mg 1000tk; 10mg 60tk

Estonia - estoński - Ravimiamet

bimeda animal health limited - deltametriin - kriipsulahus - 10mg 1ml 1000ml 1tk; 10mg 1ml 2500ml 1tk; 10mg 1ml 500ml 1tk; 10mg 1ml 250ml 1tk

Unia Europejska - estoński - EMA (European Medicines Agency)

mylan ireland limited - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Estonia - estoński - Ravimiamet

medochemie limited - tramadool - süstelahus - 50mg 1ml 2ml 5tk; 50mg 1ml 2ml 1tk

Unia Europejska - estoński - EMA (European Medicines Agency)

sanofi winthrop industrie - liksisenadiidi - suhkurtõbi, tüüp 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Unia Europejska - estoński - EMA (European Medicines Agency)

marinus pharmaceuticals emerald limited - ganaxolone - epileptic syndromes; spasms, infantile - muud antiepileptics - ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 to 17 years of age. ztalmy may be continued in patients 18 years of age and older.

Unia Europejska - estoński - EMA (European Medicines Agency)

roche registration limited - emicizumab - hemofiilia a. - antihemorraagilised ained - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra saab kasutada kõigis vanuserühmades.